Moderna Surges 69% in 2026 as Cancer Vaccine Shows Five-Year Melanoma Survival Benefits

Moderna stock jumped as five-year data from its personalized cancer vaccine trial with Merck showed a 49% reduction in melanoma recurrence risk, boosting hopes for mRNA's future in oncology.